Critical Care Medicine
Anesthesiology critical care medicine certification requires completion of a one-year fellowship in critical care medicine and passing the critical care medicine exam. Browse or search the content outline below.
-
1. Basic Pathophysiology
-
A. Central Nervous System
-
1. Altered mental status; encephalopathy; delirium
-
2. Brain death
-
3. Cerebral blood flow
-
4. Degenerative disease of the brain (e.g., Alzheimer disease, Parkinson disease)
-
5. Traumatic brain injury (TBI)
-
6. Infection
-
7. Intracranial compliance, mass lesion
-
8. Neuromuscular disorders
-
9. Seizures and status epilepticus
-
10. Spinal cord injury
-
11. Stroke
-
a. Hemorrhagic
-
b. Ischemic
-
-
12. Vascular malformations (e.g., aneurysms, AV malformations)
-
-
B. Cardiovascular
-
1. Cardiac transplantation
-
2. Congenital heart disease in adults
-
a. Eisenmenger syndrome
-
b. Tetralogy of Fallot
-
c. Intracardiac Shunts
-
d. Other
-
-
3. Coronary artery disease, myocardial ischemia/infarction
-
4. Deep Vein Thrombosis (DVT)
-
5. Hypertension
-
a. Pulmonary hypertension
-
b. Systemic hypertension
-
-
6. Infection/inflammation
-
a. Endocarditis
-
b. Myocarditis
-
c. Pericarditis
-
-
7. Myocardial function/dysfunction
-
a. Left ventricular
-
1. Diastolic dysfunction
-
2. Systolic dysfunction
-
-
b. Right ventricular
-
-
8. Peripheral vascular disease
-
a. Aneurysm, abdominal
-
b. Aneurysm, thoracic
-
c. Dissections
-
-
9. Rhythm disturbances
-
a. Asystole
-
b. Supraventricular tachyarrhythmias, including atrial flutter, atrial fibrillation
-
c. Heart block, partial or complete
-
d. Junctional or nodal rhythm
-
e. Pulseless Electrical Activity (PEA)
-
f. Ventricular tachycardia/fibrillation
-
g. Other conduction abnormalities (e.g., WPW)
-
-
10. Shock states
-
a. Cardiogenic
-
b. Distributive (e.g., sepsis, neurogenic/spinal, anaphylactic/anaphylactoid)
-
c. Hypovolemic (e.g., hemorrhagic shock)
-
d. Obstructive (e.g., pulmonary embolism)
-
-
11. Structural
-
a. Pericardial
-
b. Other myocardial
-
c. Valvular
-
1. Aortic valve
-
a. Aortic Insufficiency
-
b. Aortic Stenosis
-
c. Hypertrophic cardiomyopathy (HOCM, ASH, IHSS)
-
-
2. Mitral valve
-
a. Mitral Regurgitation
-
b. Mitral Stenosis
-
-
3. Pulmonary valve
-
a. Pulmonic insufficiency
-
b. Pulmonic stenosis
-
-
4. Tricuspid valve dysfunction
-
-
-
12. Oxygen supply and demand
-
13. Trauma
-
a. Cardiac contusion
-
b. Cardiac tamponade
-
-
14. Other (e.g., pulsus paradoxus)
-
-
C. Pulmonary
-
1. Airway diseases
-
a. Obstructive
-
b. Reactive
-
c. Restrictive
-
-
2. Aspiration
-
3. Embolic disorders
-
4. Infection
-
a. Empyema/abscess
-
b. Mediastinitis
-
c. Pneumonia
-
1. Community-acquired
-
2. Health-care associated
-
3. Ventilator-associated
-
-
d. Tracheobronchitis
-
-
5. Inflammatory and autoimmune diseases
-
6. Lung transplantation
-
7. Airway disruption
-
a. Tracheal disruption
-
b. Pneumothorax, volutrauma
-
c. Bronchopleural fistula
-
-
8. Pleural effusion
-
9. Chest trauma (e.g., pulmonary contusion, flail chest)
-
10. Pulmonary mechanics (including assessment of work of breathing)
-
11. Respiratory failure
-
a. ARDS
-
b. Hypoxemic (acute and chronic)
-
c. Hypercapnic (acute and chronic)
-
d. Other ventilation-perfusion abnormalities
-
e. Transfusion-Related Lung Injury
-
1. Transfusion-Related Acute Lung Injury (TRALI)
-
2. Transfusion associated circulatory overload (TACO)
-
-
f. Sleep apnea
-
1. Obstructive
-
2. Central
-
-
g. Pulmonary edema
-
h. Other
-
-
-
D. Renal
-
1. Infection
-
2. Renal failure
-
a. Intrinsic renal
-
b. Post-renal
-
c. Pre-renal
-
-
3. Renal tubular acidosis
-
-
E. Hematologic/Oncologic
-
1. Bone marrow/stem cell transplantation
-
2. Coagulopathies
-
a. Acquired
-
1. DIC
-
2. Isolated factor abnormalities
-
3. Vitamin K dependent coagulopathy
-
-
b. Congenital
-
-
3. Fibrinolysis
-
4. Hemoglobin abnormalities
-
a. Anemia
-
b. Polycythemia
-
c. Carboxyhemoglobin
-
d. Methemoglobin
-
e. Other hemoglobinopathies (e.g., sickle cell disease, Thalassemia)
-
-
5. Platelet abnormalities
-
a. Thrombocytosis
-
b. Thrombocytopenia
-
1. Heparin-induced thrombocytopenia
-
2. Other (e.g., thrombotic thrombocytopenic purpura, ITP)
-
-
c. Dysfunction
-
-
6. Tumor lysis syndrome
-
7. Leukemia, lymphoma
-
8. Other
-
-
F. Obstetric
-
1. Complications of pregnancy
-
a. Coagulopathy, bleeding disorders
-
b. Emboli (amniotic fluid, thromboemboli, other)
-
c. Liver function abnormalities (e.g., acute fatty liver, HELLP)
-
d. Pre-eclampsia/eclampsia
-
e. Other
-
-
2. Physiologic changes associated with pregnancy
-
3. Respiratory physiology of pregnancy
-
a. Airway changes
-
b. Pulmonary physiology
-
-
-
G. Endocrine
-
1. Adrenal
-
a. Adrenal insufficiency
-
b. Cushing syndrome
-
c. Pheochromocytoma
-
-
2. Diabetes mellitus
-
a. Hyperglycemia, including diabetic ketoacidosis (DKA), nonketotic hyperglycemic coma (NKHC)
-
b. Hypoglycemia
-
-
3. Pituitary
-
a. Cerebral salt wasting
-
b. Diabetes Insipidus, including central, nephrogenic
-
c. SIADH
-
d. Panhypopituitarism (postpartum, other)
-
-
4. Thyroid function abnormalities
-
a. Critical illness effects on thyroid function
-
b. Hyperthyroidism, including thyroid storm
-
c. Hypothyroidism, including myxedema
-
-
5. Other (e.g., carcinoid)
-
-
H. Gastrointestinal
-
1. Abdominal compartment syndrome/Intra-abdominal hypertension
-
2. Bowel disorders
-
a. Infectious
-
b. Perforation, volvulus
-
c. Pseudomembranous colitis
-
d. Bowel ischemia
-
-
3. Gall bladder disease (stones, cholecystitis)
-
4. Stomach
-
a. GI hemorrhage
-
1. Lower
-
2. Upper
-
-
b. GI motility dysfunction
-
1. Diarrhea, nausea, vomiting
-
2. Ileus
-
3. Malabsorption
-
4. Toxic megacolon
-
5. Other
-
-
-
5. Pancreas
-
a. Pancreatitis
-
b. Pancreatic cancer
-
-
6. Hepatic
-
a. Hepatic dysfunction/failure (acute and chronic)
-
b. Hepatic encephalopathy
-
c. Hepatitis
-
d. Hepatocellular carcinoma
-
e. Hepatorenal syndrome
-
f. Other
-
-
-
I. Dermatologic
-
1. Allergic reactions
-
2. Pressure injuries
-
3. Infection
-
a. Cellulitis
-
b. Necrotizing soft tissue infection
-
c. Other
-
-
4. Stevens Johnson Syndrome
-
-
J. Immunologic
-
1. Autoimmune
-
a. Mixed connective tissue disease
-
b. Rheumatoid arthritis (RA)
-
c. Systemic Lupus Erythematosis (SLE)
-
d. Vasculitides
-
e. Other
-
-
2. Immune suppression
-
a. Acquired (e.g., HIV, AIDS)
-
b. Medication related
-
-
3. Graft vs. host disease
-
-
K. Acid-base and electrolyte abnormalities
-
1. Acid-base abnormalities
-
a. Metabolic
-
b. Mixed
-
c. Respiratory
-
-
2. Electrolyte abnormalities
-
a. Calcium
-
b. Chloride
-
c. Magnesium
-
d. Phosphorus
-
e. Potassium
-
f. Sodium
-
g. Other
-
-
-
-
2. Critical Illness Diagnosis and Management
-
A. Central Nervous System
-
1. Diagnoses
-
a. Altered mental status
-
1. Coma
-
2. Delirium
-
3. Hallucinations
-
4. Other (e.g., hypoxic/metabolic encephalopathy)
-
-
b. Brain death
-
c. Degenerative disease of the brain (e.g., Alzheimer disease, Parkinson disease)
-
d. Traumatic brain injury (TBI) (subarachnoid, subdural, epidural hematoma)
-
e. Infectious
-
1. Abscess
-
2. Encephalitis
-
3. Meningitis/ventriculitis
-
-
f. Neuromuscular disorders
-
1. Critical illness polyneuropathy/myopathy
-
2. Demyelinating
-
3. Guillain-Barré syndrome
-
4. Myasthenia gravis
-
5. Myopathy
-
6. Other
-
-
g. Seizures and status epilepticus
-
h. Spinal cord injury
-
i. Stroke
-
1. Hemorrhagic (Subarachnoid, hypertensive, hemorrhagic conversion)
-
2. Ischemic
-
-
j. Tumors (supratentorial, infratentorial, spinal)
-
k. Vascular malformations (e.g., aneurysms, AV malformations)
-
l. Pituitary disorders (e.g., acromegaly, infarction)
-
m. Other psychiatric disorders (e.g., depression, anxiety, PTSD)
-
-
2. Diagnostic modalities
-
a. Angiography
-
b. EEG, processed EEG
-
c. Evoked potential
-
d. ICP measurement
-
e. Other imaging (e.g., CT, CTA, MRI, MRA)
-
f. Jugular venous saturation
-
g. Lumbar puncture
-
h. Nerve conduction studies/EMG
-
i. Nuclear medicine studies (e.g., cerebral blood flow)
-
j. Transcranial Doppler
-
k. Other
-
-
3. Management strategies
-
a. Anticonvulsants
-
b. Antimicrobials
-
c. ICP-controlling medications
-
d. Interventional radiology (e.g., coiling, clipping, vasospasm therapies)
-
e. Neuroprotectants
-
f. Steroids
-
g. Surgical interventions
-
h. Vasoactive drugs
-
i. Plasmapheresis/plasma exchange
-
j. Other therapies, e.g., CSF drainage
-
k. Antidepressants
-
1. Tricyclic antidepressants
-
2. SSRIs
-
3. Lithium
-
4. Other
-
-
l. Antipsychotics
-
m. Neuromuscular blocking drugs
-
n. Thrombolytics
-
-
-
B. Cardiovascular
-
1. Diagnoses
-
a. Cardiac transplantation, rejection, complications
-
b. Congenital heart disease in adults
-
1. Eisenmenger syndrome
-
2. Tetralogy of Fallot
-
3. Other
-
-
c. Coronary artery disease, myocardial ischemia/infarction
-
d. Hypertension
-
1. Pulmonary hypertension
-
2. Systemic hypertension
-
-
e. Infectious
-
1. Endocarditis
-
2. Myocarditis
-
3. Pericarditis
-
-
f. Myocardial function/dysfunction
-
1. Left ventricular
-
a. Diastolic dysfunction
-
b. Systolic dysfunction
-
-
2. Right ventricular
-
-
g. Peripheral vascular disease
-
1. Aneurysms, thoracic
-
2. Aneurysm, abdominal
-
3. Dissections
-
4. Other
-
-
h. Rhythm disturbances
-
1. Asystole
-
2. Atrial flutter/fibrillation
-
3. Supraventricular tachyarrhythmias, other
-
4. Heart block
-
5. Junctional or nodal rhythm
-
6. Pulseless Electrical Activity (PEA)
-
7. Ventricular tachycardia/fibrillation
-
8. Other conduction abnormalities (e.g., WPW)
-
-
i. Shock states
-
1. Cardiogenic
-
2. Distributive (e.g., sepsis, neurogenic/spinal, anaphylactic/anaphylactoid)
-
3. Hypovolemic (e.g., hemorrhagic shock)
-
4. Obstructive (e.g., pulmonary embolism)
-
-
j. Structural
-
1. Cardiac contusion
-
2. Acquired ASD, VSD
-
3. Cardiomyopathy
-
4. Non-infectious myocarditis
-
5. Papillary muscle dysfunction
-
6. Stunned myocardium
-
7. Stress-induced cardiomyopathy (e.g., Takotsubo cardiomyopathy)
-
8. Pericardial
-
a. Pericardial effusion
-
b. Pericarditis
-
c. Tamponade
-
-
9. Systemic oxygen supply and demand
-
10. Traumatic
-
11. Valvular
-
a. Aortic
-
1. Insufficiency
-
2. Stenosis
-
3. Hypertrophic cardiomyopathy (HOCM, ASH, IHSS)
-
-
b. Mitral
-
1. Regurgitation
-
2. Stenosis
-
-
c. Pulmonic valve disease
-
1. Regurgitation
-
2. Stenosis
-
-
d. Tricuspid valve disease
-
-
12. Other (e.g., Noncardiogenic pulmonary edema, pulsus paradoxus)
-
-
-
2. Diagnostic modalities
-
a. Hemodynamic monitoring
-
1. Arterial pressure
-
2. Cardiac output monitoring
-
3. CVP
-
4. ECG
-
5. Pulse pressure/stroke volume variation
-
6. Other
-
-
b. Imaging
-
1. CT, MRI
-
2. Interventional imaging
-
3. Nuclear imaging
-
-
-
3. Management strategies
-
a. Anticoagulants and antithrombotics
-
1. Antiplatelet agents
-
2. Heparin
-
a. Heparinoids
-
b. LMWH
-
c. Unfractionated
-
-
3. Thrombin inhibitors (e.g., bivalirudin, argatroban)
-
4. Thrombolytics
-
5. Antifibrinolytics
-
6. Warfarin
-
7. Direct Oral Anticoagulants (DOACs)
-
8. Other
-
-
b. Antidysrhythmics
-
c. Antimicrobials
-
d. Circulatory support systems
-
1. ECMO
-
2. Pacemakers/defibrillators
-
a. AICDs
-
b. External defibrillators
-
c. Transthoracic
-
d. Transvenous/epicardial
-
-
3. Left or right ventricular assist device (open or percutaneous)
-
4. Intraaortic balloon pump
-
-
e. Pericardiocentesis
-
f. Vasoactive or modulating drugs
-
1. Antihypertensives
-
2. Inotropes/chronotropes/lusitropes
-
3. Vasoconstrictors
-
4. Vasodilators (systemic or pulmonary)
-
-
g. Other
-
-
-
C. Pulmonary
-
1. Diagnoses
-
a. Airway diseases
-
1. Obstructive
-
2. Reactive
-
3. Restrictive
-
-
b. Airway disruption (e.g., pneumothorax, volutrauma)
-
c. Aspiration
-
d. Chest trauma (e.g., pulmonary contusion, flail chest)
-
e. Embolic disorders
-
1. Air
-
2. Fat
-
3. Thromboembolic
-
4. Other
-
-
f. Infection
-
1. Empyema/abscess
-
2. Mediastinitis
-
3. Pneumonia
-
a. Community-acquired
-
b. Health care associated
-
c. Ventilator associated
-
-
4. Tracheobronchitis
-
-
g. Inflammatory and autoimmune diseases
-
h. Lung and chest wall tumors
-
i. Lung transplantation (rejection, complications)
-
j. Pleural effusion
-
k. Pulmonary edema
-
l. Respiratory failure
-
1. ARDS
-
2. Hypercapnic (acute and chronic)
-
3. Hypoxic (acute and chronic)
-
4. TRALI
-
5. Other
-
-
m. Volutrauma/barotrauma
-
n. Inhalation injuries
-
-
2. Diagnostic modalities
-
a. Blood gas (arterial, venous)
-
b. Capnography
-
c. Imaging
-
1. Chest x-ray
-
2. CT/MRI
-
3. Nuclear studies
-
4. Ultrasound
-
-
d. Laryngoscopy and bronchoscopy
-
e. Pulmonary function studies/pulmonary mechanics
-
f. Pulse oximetry
-
g. Sleep studies
-
h. Thoracentesis
-
-
3. Management strategies
-
a. Antimicrobials/antivirals/antifungals
-
b. Management of bronchopleural and bronchocutaneous fistulae
-
c. Pleural drainage and evacuation (e.g., thoracentesis, chest tube placement)
-
d. Pulmonary medications
-
e. Vaccination (Pneumovax)
-
f. Ventilatory support
-
1. Invasive ventilation modes
-
a. Airway pressure-release ventilation
-
b. Assist control
-
c. High-frequency/oscillation
-
d. PC/volume control
-
e. Pressure-support ventilation
-
f. SIMV
-
-
2. Noninvasive
-
a. BiPAP
-
b. CPAP
-
-
3. Spontaneous breathing trials
-
4. Other ventilator strategies
-
a. Differential lung ventilation
-
b. Positioning (e.g., prone)
-
-
-
g. Extracorporeal support (e.g., VV ECMO)
-
-
-
D. Renal
-
1. Diagnoses
-
a. Infection
-
b. Renal failure
-
1. Contrast induced-nephropathy
-
2. Intrinsic renal
-
3. Post-renal
-
4. Pre-renal
-
5. Renal tubular acidosis
-
6. Hepatorenal syndrome
-
7. Rhabdomyolysis
-
-
c. Renal trauma
-
d. Renal transplantation (e.g., rejection)
-
-
2. Diagnostic modalities
-
a. Electrolytes, osmolarity, and specific gravity (serum, urine)
-
b. Imaging
-
1. Angiography
-
2. CT/MRI
-
3. Diagnostic x-ray
-
4. Ultrasound
-
-
c. Renal biopsy
-
-
3. Management strategies
-
a. Fluid and electrolyte management
-
b. Pharmacologic therapies
-
1. Antimicrobials/antifungals
-
2. Buffers
-
3. Diuretic therapy
-
4. N-acetylcysteine
-
-
c. Renal replacement therapies
-
1. Continuous renal replacement therapies including ultrafiltration
-
2. Intermittent hemodialysis
-
3. Peritoneal dialysis
-
-
-
-
E. Hematologic/Oncologic
-
1. Diagnoses
-
a. Bone marrow/stem cell transplantation (rejection, complications)
-
b. Coagulopathies
-
1. Acquired
-
a. DIC
-
b. Isolated factor abnormalities
-
c. Vitamin K dependent
-
-
2. Congenital
-
-
c. Fibrinolysis
-
d. Hemoglobin abnormalities
-
1. Anemia
-
2. Polycythemia
-
3. Carboxyhemoglobin
-
4. Methemoglobin
-
5. Other hemoglobinopathies (e.g., sickle cell disease, Thalassemia)
-
-
e. Hypercoagulable state
-
f. Platelet abnormalities
-
1. Thrombocytopenia (including HIT)
-
2. Thrombocytosis
-
3. Other (e.g., thrombocytopenic purpura, ITP)
-
-
g. Tumor lysis syndrome
-
h. White blood cell disorder
-
i. Leukemia, lymphoma
-
j. Other
-
-
2. Diagnostic modalities
-
a. Bone marrow biopsy, culture
-
b. Coagulation studies (e.g., PT, PTT, TEG, ROTEM, factor levels)
-
c. Routine blood studies (e.g., CBC, platelets)
-
-
3. Management strategies
-
a. Anticoagulants
-
1. Heparin
-
a. LMWH
-
b. Unfractionated
-
-
2. Warfarin
-
3. Antiplatelet agents
-
4. Thrombin inhibitors (e.g., argatroban)
-
5. Thrombolytics
-
6. Factor Xa inhibitors
-
-
b. Erythropoietin, GCSF
-
c. Plasmapheresis/plasma exchange
-
d. Transfusion and factor replacement
-
e. IVC filters, other mechanical devices
-
f. Other
-
-
-
F. Obstetric
-
1. Diagnoses
-
a. Coagulopathy, bleeding disorders
-
b. Emboli (amniotic fluid, thromboemboli, other)
-
c. Liver function abnormalities (e.g., acute fatty liver, HELLP)
-
d. Pre-eclampsia/eclampsia
-
e. Peripartum infection
-
f. Trauma in obstetric patients
-
g. Other
-
-
2. Diagnostic modalities
-
a. Laboratory studies (serum, urine)
-
b. Ultrasound
-
c. Cardiotocography
-
-
3. Management strategies
-
a. Anticoagulants
-
b. Anticonvulsants
-
c. Antihypertensive therapy
-
d. Antimicrobials
-
e. Delivery
-
-
-
G. Endocrine
-
1. Diagnoses
-
a. Adrenal
-
1. Adrenal insufficiency
-
2. Cushing syndrome
-
3. Pheochromocytoma
-
-
b. Diabetes mellitus
-
1. Hyperglycemia [diabetic ketoacidosis (DKA), non-ketotic hyperglycemic coma (NKHC)]
-
2. Hypoglycemia
-
-
c. Pituitary
-
1. Cerebral salt wasting
-
2. Diabetes insipidus (central, nephrogenic)
-
3. SIADH
-
-
d. Thyroid function abnormalities
-
1. Critical illness effects on thyroid function
-
2. Hyperthyroidism, including thyroid storm
-
3. Hypothyroidism, including myxedema
-
-
e. Other
-
-
2. Diagnostic modalities
-
a. CT
-
b. Laboratory studies (serum, urine)
-
c. Ultrasound
-
-
3. Management strategies
-
a. Antihypertensives
-
b. Hormone replacement therapy
-
c. Glucose management
-
1. Insulin
-
2. Oral hypoglycemic agents
-
3. Other therapies
-
-
d. Steroids (glucocorticoid and mineralocorticoid)
-
e. Vasodilators
-
f. Vasopressin/DDAVP
-
-
-
H. Gastrointestinal
-
1. Diagnoses
-
a. Abdominal compartment syndrome
-
b. Bowel disorders
-
c. Gall bladder disease (stones, cholecystitis)
-
d. Stomach
-
1. Gastritis
-
2. Ulcer
-
-
e. GI hemorrhage (upper, lower)
-
f. GI motility dysfunction, GERD
-
g. Pancreas
-
1. Pancreatitis
-
2. Pancreatic cancer
-
-
h. Hepatic
-
1. Dysfunction/failure, acute and chronic
-
2. Hepatic encephalopathy
-
3. Hepatitis
-
4. Hepatocellular carcinoma
-
5. Hepatorenal syndrome
-
6. Liver transplantation, rejection, complications
-
-
i. Abdominal trauma (i.e., splenic, liver, bowel injuries)
-
j. Other
-
-
2. Diagnostic modalities
-
a. Abdominal pressure measurement (bladder pressure, other)
-
b. Assessment of bowel motility
-
c. Endoscopy, upper, lower
-
d. Imaging (CT, MRI, x-ray, nuclear medicine studies, ultrasound)
-
e. Interventional radiology
-
f. Laboratory Studies
-
1. Coagulation parameters
-
2. Immunologic studies
-
3. Nutritional assessment (albumin, prealbumin)
-
4. Routine blood studies (CBC, electrolytes, renal function)
-
5. Stool assessment (occult blood, C. diff toxin)
-
6. Serology (hepatitis, HIV)
-
7. Additional relevant studies (e.g., amylase, lipase)
-
8. Other
-
-
g. Biopsy (e.g., liver)
-
h. Endoscopy (upper, lower); ERCP
-
i. Imaging (x-ray, CT, MRI, ultrasound)
-
j. Paracentesis, diagnostic
-
-
3. Management strategies
-
a. Blood product selection and administration
-
b. Diuretics, renal replacement therapies
-
c. Endoscopy, upper, lower with therapeutic intervention
-
d. Immunotherapy (e.g., IgG)
-
e. Interventional radiology (embolization, coiling)
-
f. Management of increased intra-abdominal pressure
-
g. Nutritional support (enteral, parenteral)
-
h. Paracentesis, therapeutic
-
i. Pharmacologic management
-
1. Antimicrobials
-
2. GI blood flow modulators
-
3. Immunologic therapy, steroids
-
4. Lactulose, rifaximin
-
5. Other
-
-
j. Surgical intervention (timing, therapeutic options)
-
k. Vaccination (e.g., hepatitis)
-
-
-
I. Dermatologic
-
1. Diagnoses
-
a. Allergic reactions
-
b. Disruption of the skin barrier, including decubiti, Stevens-Johnson syndrome
-
c. Infection
-
1. Cellulitis
-
2. Necrotizing soft tissue infection
-
3. Other
-
-
d. Inflammatory diseases of the skin
-
e. Stevens Johnson Syndrome
-
f. Burns
-
-
2. Diagnostic modalities, laboratory studies
-
a. CBC with differential
-
b. Immunologic studies
-
c. Sedimentation rate
-
-
3. Management strategies
-
a. Pharmacologic
-
1. Antimicrobials
-
2. Antihistamines
-
3. Immunotherapies (systemic and topical)
-
4. Other
-
-
b. Fluids and resuscitation
-
c. Wound care (surgical and other)
-
d. Hyperbaric therapy
-
-
-
J. Immunologic
-
1. Diagnoses
-
a. Autoimmune
-
1. Mixed connective tissue disease
-
2. RA
-
3. SLE
-
4. Vasculitides
-
5. Other
-
-
b. Graft vs. host disease
-
c. Immune suppression (e.g., HIV, AIDS)
-
-
2. Diagnostic modalities
-
a. Biopsy, selective aspiration
-
b. Laboratory studies
-
1. Immunologic studies
-
2. Routine (CBC, etc.)
-
3. Serologies
-
-
-
3. Management strategies
-
a. Pharmacologic
-
1. Antimicrobial therapy
-
2. Antimicrobial prophylaxis
-
3. HAART
-
4. Immunosuppression (glucocorticoids, antimetabolites, calcineurin inhibitors)
-
5. Other
-
-
-
-
K. Acid-base and electrolyte abnormalities
-
1. Diagnoses
-
a. Acid-base abnormalities
-
1. Metabolic
-
2. Mixed
-
3. Respiratory
-
-
b. Electrolyte abnormalities
-
1. Calcium
-
2. Chloride
-
3. Magnesium
-
4. Phosphorus
-
5. Potassium
-
6. Sodium
-
7. Other
-
-
-
2. Diagnostic modalities
-
a. Laboratory studies
-
1. Albumin
-
2. Arterial blood gas
-
3. Electrolytes, osmolarity, and specific gravity (serum, urine)
-
-
b. Selective imaging
-
-
3. Management strategies
-
a. Appropriate renal and endocrine strategies
-
b. Electrolyte management
-
c. Ventilatory support
-
-
-
-
3. Specialized Areas
-
A. Biostatistics
-
1. Number needed to treat
-
2. Odds ratio
-
3. Regression analysis
-
4. Relative risk
-
5. ROC
-
6. Positive Predictive Value/Negative Predictive Value
-
7. Sensitivity, specificity
-
8. Statistical significance (p-value)
-
9. Confidence Interval
-
10. Statistical tests
-
a. Non-parametric (e.g., Wilcoxon, Mann Whitney U test, Chi squared, Kaplan Meier curve)
-
b. Parametric (e.g., t-test, ANOVA)
-
-
11. Type 1 and type 2 errors
-
-
B. Disaster Management
-
1. Triage
-
2. Biologic, chemical, and nuclear exposures
-
3. Epidemic (e.g., COVID-19, SARS, bird flu, toxic exposures)
-
-
C. Drowning
-
1. Fresh water
-
2. Salt water
-
-
D. ICU Ethics
-
1. Brain death
-
2. End-of-life, futility
-
3. Impaired providers
-
4. Informed consent
-
5. Living will/DPOA/Healthcare surrogate
-
6. Organ donation
-
7. Palliative care, hospice
-
8. Patient autonomy
-
-
E. ICU Management and Organization
-
1. Clinical care bundles and guidelines (e.g., sepsis, catheter management)
-
2. Compliance
-
3. Daily wake-up test
-
4. HIPAA (privacy and security)
-
5. ICU transport
-
6. Outcome and performance measures (HCAPS)
-
7. Regulatory requirements
-
8. Scoring systems (e.g., APACHE, SOFA)
-
9. Sedation/analgesia/delirium assessment (e.g., CAM-ICU, RASS)
-
10. Triage and resource utilization
-
11. Telemedicine
-
-
F. Infection Control
-
1. Environmental exposures
-
2. Isolation techniques
-
a. General/universal precautions
-
b. Reverse isolation
-
c. Specific isolation procedures
-
-
3. Needle stick injuries
-
4. Nosocomial infections
-
a. Catheter associated infections
-
b. Pneumonia (ventilator associated, hospital associated, etc.)
-
c. UTI, catheter-associated UTI
-
d. Other
-
-
-
G. Life Support and Resuscitation
-
1. ACLS
-
2. ATLS
-
3. Other
-
-
H. Nutrition Management
-
1. Enteral and parenteral nutrition (formula, caloric intake)
-
2. Metabolic assessment (basal and stress energy requirements)
-
a. Indirect calorimetry
-
b. Nitrogen balance
-
c. Other
-
-
3. Re-feeding syndrome
-
-
I. Pain and Sedation Management
-
1. Systemic analgesia (indications, contraindications, complications)
-
2. Regional analgesia (indications, contraindications, complications
-
-
J. Pharmacology (Indications, Contraindications, and Complications)
-
1. Antidepressants
-
a. Tricyclic antidepressants
-
b. SSRIs
-
c. Lithium
-
d. Other
-
-
2. Antimicrobials
-
a. Antibiotics
-
1. Anaerobes
-
2. Gram-negative organisms
-
3. Gram-positive organisms
-
4. Spirochetal and rickettsial
-
5. TB
-
6. Other
-
-
b. Antifungal
-
c. Antimicrobial resistance
-
d. Antiparasitic
-
e. Antiviral
-
f. Prophylactic antimicrobials
-
-
3. Antipsychotics
-
4. Genetic considerations
-
5. Pharmacokinetics and pharmacodynamics and drug metabolism
-
6. Neuromuscular blocking drugs
-
7. Sedatives/hypnotics
-
8. Immunosuppressants
-
9. Other
-
-
K. Poisonings, Toxic Ingestion, Overdoses
-
L. Procedures
-
1. Airway
-
a. LMA/others
-
b. Tracheostomy and cricothyrotomy
-
c. Transtracheal tubes
-
-
2. Monitoring techniques and troubleshooting (e.g., cardiac, neurologic, etc.)
-
3. Ultrasound (indications, physics and interpretation)
-
a. Cardiac (transthoracic, transesophageal)
-
b. Thoracic
-
c. Vascular
-
d. Abdominal, including gastric
-
e. Ocular
-
f. Other
-
-
4. Vascular access
-
a. Arterial
-
b. Intraosseous
-
c. Venous
-
-
-
M. Thermoregulation
-
1. Hyperthermia
-
a. Heat stroke
-
b. Fever
-
c. Malignant hyperthermia
-
d. Neuroleptic malignant syndrome
-
e. Serotonin syndrome
-
-
2. Hypothermia
-
a. Environmental
-
-
-
N. Diversity, Equity, and Inclusion (DEI) in health care
-
1. Barriers
-
a. Systematic racism, colorism/shadeism, sexism, discrimination against sexual orientation, gender identity,language, national origin, ethnicity, religion, immigration/citizenship status, age, familial status, and disability
-
b. Bias; Implicit bias, microaggression, stereotype threat
-
-
2. Approaches to improvement; interventions at individual, inter-personal, community, organizational and policy levels; cultural and gender competency, upstander vs. bystander, allyship vs. performative action, tokenism vs. representation, assortativity vs. homophily
-
3. DEI in the workplace
-
4. DEI in academia
-
a. Leadership
-
b. Scholarship; Representation of diversity and race related topics in research, Importance of language in reports discussing racial inequities
-
-
-
O. Healthcare Disparities
-
1. Social determinants of health considerations in assessment and management of patients – race, language, education status, religion, housing, nutrition, geographic location, rural vs. urban, access to and quality of care, health coverage
-
2. Maternal healthcare disparities; Maternal mortality and morbidity, Pain management
-
3. Child and adolescent healthcare disparities
-
4. ICU disparities and outcomes
-
-
P. Ethics and Medico-Legal Issues
-
1. Professionalism: definitions and teaching
-
a. Disclosure of errors or adverse events
-
b. Professional behavior: honesty, integrity, compassion, respect, altruism, conflicts of interest, response to marketing
-
c. Recognizing limitations in expertise and need to seek guidance
-
d. Personal role in reporting unsafe conditions and fitness for work
-
e. Recognizing and responding to unprofessional behavior
-
f. Evidence-based practice
-
-
2. Patient autonomy and decision making
-
a. Principles of informed consent and shared decision making
-
b. Advance Directives, Do Not Resuscitate (DNR) Orders, medical orders for life-sustaining treatment
-
c. Health care proxy laws and limitations
-
d. Patients Refusing Transfusion or Other Treatments
-
-
3. Legal and regulatory issues
-
a. Elements of medical malpractice: duty, breath of duty, causation, damages
-
b. Legal actions and consequences, National Practitioner Data Bank, Closed Claims findings, professional liability insurance
-
c. Understanding laws related to controlled substances, including opioids and cannabinoids
-
d. Patient privacy issues: principles of confidentiality, access to records, protected health information
-
e. The Health Insurance Portability and Accountability Act (HIPAA)
-
-
4. Primary Certification, Recertification, Maintenance of Certification and Related Issues (Professional Standing, Lifelong Learning, Cognitive Knowledge, Clinical Practice Assessment, Systems-Based Practice)
-
5. Research ethics
-
a. Principles of justice, autonomy, beneficence, nonmalfeasance
-
b. Ethical standards in research design: scientific validity, fair subject selection, favorable risk-benefit profile
-
c. Review and implementation of trials, the institutional review board
-
d. Informed consent in research
-
e. Conflicts of interest and financial disclosure
-
-
6. Clinician wellness and self-care
-
a. Diagnosis and treatment of burnout
-
b. Sleep deprivation
-
c. Adaptations for clinical disability
-
d. Substance abuse
-
-
-
Q. Practice Management
-
1. Costs of medical/anesthesia care
-
a. Understanding principles of healthcare funding and payment
-
b. Cost-conscious practice
-
-
2. Efficient OR staffing and scheduling
-
a. Subspecialization issues: pediatrics, cardiac, regional, obstetric coverage
-
b. Anesthesia care team and scope of practice
-
-
3. Population health: perioperative surgical home and enhanced recovery
-
a. Population based health determinants, resources to improve access
-
b. Health care disparities between populations
-
-
4. Clinical informatics
-
a. Electronic medical record systems: costs and benefits
-
b. Artificial intelligence and machine learning
-
-
5. Documentation, coding, and billing
-
a. Compliance with documentation requirements
-
b. Accuracy, clarity, specificity of medical records
-
c. Coding integrity, audits, and insurance denials
-
-
-
R. Quality Improvement and Patient Safety
-
1. Definitions
-
a. Medical error, adverse events, sentinel events, misuse of medications and technology
-
b. Human factors and mindfulness
-
c. Systems thinking and technology design
-
-
2. Medication errors: assessment and prevention
-
a. Medication reconciliation
-
b. Information technology to reduce medication errors
-
-
3. Crisis Management and Teamwork
-
a. Simulation training
-
b. Crisis manuals and other cognitive aids
-
c. Teamwork training
-
d. Handoff communication
-
e. Preoperative and procedural checklists
-
-
4. Quality Improvement (QI) Basics
-
a. Design, Analysis, and implementation of QI projects
-
b. Data collection
-
c. QI metrics
-
d. Patient satisfaction measurement
-
e. Value-based care incentives, pay-for-performance
-
-
5. Performance Assessment
-
a. Individual benchmarking
-
b. Group and facility scorecards
-
c. Public reporting
-
1. Federal Quality Payment Program
-
2. Anesthesia registries
-
-
-
6. Change Management Methods
-
a. Peer review and morbidity and mortality Conferences
-
b. Lean Six Sigma
-
c. QI and the 5S process
-
d. Value stream mapping
-
e. Failure mode and effects analysis
-
f. Root cause analysis
-
-
7. Barriers to QI
-
-
Study Resources
Amanda Xi: How I studied for the ABA critical care medicine board exam/certification (2022)
Alex Yartsev's Deranged Physiology, focused on preparation for New Zealand's CICM Part 2